Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint Autonomix Medical Inc’s next R&D milestone or decode its FDA pathway can feel overwhelming when those details are buried in hundreds of pages of SEC text. Early-stage medical device disclosures mix engineering jargon with clinical trial data, making it hard to see how a single catheter-based innovation might affect revenue or dilution.
Stock Titan solves this by combining real-time EDGAR feeds with AI-powered summaries that translate every form into plain English. Whether you need the Autonomix Medical Inc annual report 10-K simplified for risk factors, an Autonomix Medical Inc quarterly earnings report 10-Q filing for burn-rate trends, or an Autonomix Medical Inc 8-K material events explained update on a breakthrough study, our system highlights what matters in seconds. You’ll also see Autonomix Medical Inc insider trading Form 4 transactions the moment they post, with alerts on Autonomix Medical Inc Form 4 insider transactions real-time.
Below you’ll find every document—10-K, 10-Q, 8-K, S-1, DEF 14A, and more—plus AI context so understanding Autonomix Medical Inc SEC documents with AI becomes routine. Use the data to:
- Compare R&D spend quarter over quarter with Autonomix Medical Inc earnings report filing analysis
- Track Autonomix Medical Inc executive stock transactions Form 4 before key announcements
- Review the Autonomix Medical Inc proxy statement executive compensation to align incentives
No more skimming dense exhibits—our platform surfaces neural-signal technology disclosures, capital-raise details, and clinical milestones in one intuitive view. Complex filings made clear, right when you need them.
On July 1, 2025, Covenant Logistics Group, Inc. (CVLG) Executive Vice President & Chief Operating Officer Dustin Koehl reported insider activity on SEC Form 4.
- RSU conversion (Code M): 2,820 restricted stock units were converted into an equal number of Class A common shares.
- Tax withholding (Code F): 687 of those shares were immediately surrendered at $25.23 per share to satisfy statutory tax obligations.
- Net ownership change: Koehl’s direct holdings rose by 2,133 shares, bringing his direct stake to that amount after the transactions.
- Remaining equity incentives: 5,640 RSUs remain outstanding under the Third Amended & Restated 2006 Omnibus Incentive Plan, vesting in three equal annual installments starting July 1, 2025.
- Capital structure note: All figures reflect the two-for-one stock split effected as a stock dividend on December 31, 2024.
The filing indicates continued equity alignment by a key executive through scheduled incentive-plan vesting rather than discretionary open-market purchases.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
What is the primary focus of Autonomix Medical Inc?
How does the company’s technology platform work?
What sets Autonomix Medical Inc apart from other medical device companies?
How does Autonomix generate value as a development-stage company?
What are the key challenges faced by companies in this sector?
Who are the target customers for Autonomix Medical’s innovations?
